SCHEMBL20430360

SCHEMBL20430360

CCC(=O)Nc1nn(C)c2c(I)ccc(Cl)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.40
▸ KDM4E B2RXH2 4/20 0.39
▸ HTT P42858 4/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ TSHR P16473 3/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CCR6 P51684 1/20 0.35
▸ MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16158005 0.86 KDM4E (0.45) CYP3A4KDM4EHTTHSD17B10MAPT
SCHEMBL17697579 0.86 CYP3A4 (0.41) CYP3A4KDM4EHTTHSD17B10MAPT
SCHEMBL25639161 0.82 CYP3A4 (0.39) CYP3A4KDM4EHTTHSD17B10MAPT
SCHEMBL19788770 0.82 CYP3A4 (0.39) CYP3A4KDM4EHTTHSD17B10MAPT
SCHEMBL23653934 0.81 CNR2 (0.33) KDM4EHTTMAPTALDH1A1SMN1; SMN2
SCHEMBL16006819 0.80 CRHR1 (0.38) KDM4E
SCHEMBL17761168 0.78 PDE2A (0.30) —
SCHEMBL17621602 0.76 SMN1; SMN2 (0.37) CYP3A4KDM4EHTTHSD17B10MAPT
SCHEMBL16006422 0.75 ALDH1A1 (0.43) KDM4EHTTHSD17B10MAPTCASP1
SCHEMBL16157903 0.74 ALDH1A1 (0.43) KDM4EHTTHSD17B10MAPTCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961742-B1 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2018-08-01 — — EP disclosed
Send feedback